Te Poele RH - Search Results

1

Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling.

Stockwell SR, Platt G, Barrie SE, Zoumpoulidou G, Te Poele RH, Aherne GW, Wilson SC, Sheldrake P, McDonald E, Venet M, Soudy C, Elustondo F, Rigoreau L, Blagg J, Workman P, Garrett MD, Mittnacht S. Stockwell SR, et al. Among authors: te poele rh. PLoS One. 2012;7(1):e28568. doi: 10.1371/journal.pone.0028568. Epub 2012 Jan 12. PLoS One. 2012. PMID: 22253692 Free PMC article.

2

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.

Clarke PA, te Poele R, Wooster R, Workman P. Clarke PA, et al. Biochem Pharmacol. 2001 Nov 15;62(10):1311-36. doi: 10.1016/s0006-2952(01)00785-7. Biochem Pharmacol. 2001. PMID: 11709192 Review.

3

Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status.

Kote-Jarai Z, Williams RD, Cattini N, Copeland M, Giddings I, Wooster R, tePoele RH, Workman P, Gusterson B, Peacock J, Gui G, Campbell C, Eeles R. Kote-Jarai Z, et al. Clin Cancer Res. 2004 Feb 1;10(3):958-63. doi: 10.1158/1078-0432.ccr-1067-3. Clin Cancer Res. 2004. PMID: 14871973

4

Gene expression microarray technologies in the development of new therapeutic agents.

Clarke PA, te Poele R, Workman P. Clarke PA, et al. Eur J Cancer. 2004 Nov;40(17):2560-91. doi: 10.1016/j.ejca.2004.07.024. Eur J Cancer. 2004. PMID: 15541959 Review.

5

Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival.

Renshaw J, Orr RM, Walton MI, Te Poele R, Williams RD, Wancewicz EV, Monia BP, Workman P, Pritchard-Jones K. Renshaw J, et al. Mol Cancer Ther. 2004 Nov;3(11):1467-84. Mol Cancer Ther. 2004. PMID: 15542786

6

Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways.

Knowles HJ, te Poele RH, Workman P, Harris AL. Knowles HJ, et al. Among authors: te poele rh. Biochem Pharmacol. 2006 Feb 28;71(5):646-56. doi: 10.1016/j.bcp.2005.11.019. Epub 2006 Jan 18. Biochem Pharmacol. 2006. PMID: 16386710

7

AHR- and DNA-damage-mediated gene expression responses induced by benzo(a)pyrene in human cell lines.

Hockley SL, Arlt VM, Brewer D, Te Poele R, Workman P, Giddings I, Phillips DH. Hockley SL, et al. Chem Res Toxicol. 2007 Dec;20(12):1797-810. doi: 10.1021/tx700252n. Epub 2007 Oct 19. Chem Res Toxicol. 2007. PMID: 17944540

8

The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.

Whittaker SR, Te Poele RH, Chan F, Linardopoulos S, Walton MI, Garrett MD, Workman P. Whittaker SR, et al. Among authors: te poele rh. Cell Cycle. 2007 Dec 15;6(24):3114-31. doi: 10.4161/cc.6.24.5142. Epub 2007 Oct 5. Cell Cycle. 2007. PMID: 18075315

9

Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity.

Chan F, Sun C, Perumal M, Nguyen QD, Bavetsias V, McDonald E, Martins V, Wilsher NE, Raynaud FI, Valenti M, Eccles S, Te Poele R, Workman P, Aboagye EO, Linardopoulos S. Chan F, et al. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3147-57. doi: 10.1158/1535-7163.MCT-07-2156. Mol Cancer Ther. 2007. PMID: 18089709

10

Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma.

Guillard S, Clarke PA, Te Poele R, Mohri Z, Bjerke L, Valenti M, Raynaud F, Eccles SA, Workman P. Guillard S, et al. Cell Cycle. 2009 Feb 1;8(3):443-53. doi: 10.4161/cc.8.3.7643. Epub 2009 Feb 16. Cell Cycle. 2009. PMID: 19177002

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

31 results

Search Page